These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3537218)

  • 1. High-dose chemotherapy without autologous bone marrow transplantation in melanoma.
    Tchekmedyian NS; Tait N; Van Echo D; Aisner J
    J Clin Oncol; 1986 Dec; 4(12):1811-8. PubMed ID: 3537218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
    Phillips GL; Fay JW; Herzig GP; Herzig RH; Weiner RS; Wolff SN; Lazarus HM; Karanes C; Ross WE; Kramer BS
    Cancer; 1983 Nov; 52(10):1792-802. PubMed ID: 6354414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma.
    Hartmann O; Benhamou E; Beaujean F; Kalifa C; Lejars O; Patte C; Behard C; Flamant F; Thyss A; Deville A
    J Clin Oncol; 1987 Aug; 5(8):1205-11. PubMed ID: 3305792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease.
    Ahmed T; Ciavarella D; Feldman E; Ascensao J; Hussain F; Engelking C; Gingrich S; Mittelman A; Coleman M; Arlin ZA
    Leukemia; 1989 Jan; 3(1):19-22. PubMed ID: 2642573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
    J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
    Attal M; Canal P; Schlaifer D; Chatelut E; Dezeuze A; Huguet F; Payen C; Pris J; Laurent G
    J Clin Oncol; 1994 Jan; 12(1):141-8. PubMed ID: 8270970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy with autologous bone marrow support in advanced malignant melanoma.
    Koeppler H; Pflueger KH; Seitz R; Havemann K
    Onkologie; 1989 Dec; 12(6):277-9. PubMed ID: 2696912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE; Barnett MJ; Connors JM; Fairey RN; Fay JW; Greer JP; Herzig GP; Herzig RH; Klingemann HG; LeMaistre CF
    J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
    Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P
    Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.
    Pfreundschuh MG; Rueffer U; Lathan B; Schmitz N; Brosteanu O; Hasenclever D; Haas R; Kirchner H; Koch P; Kuse R
    J Clin Oncol; 1994 Mar; 12(3):580-6. PubMed ID: 8120557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
    Alessandrino EP; Bernasconi P; Colombo A; Caldera D; Martinelli G; Vitulo P; Malcovati L; Nascimbene C; Varettoni M; Volpini E; Klersy C; Bernasconi C
    Bone Marrow Transplant; 2000 Feb; 25(3):309-13. PubMed ID: 10673703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.
    Papadakis V; Dunkel IJ; Cramer LD; Kramer E; Papadopoulos E; Goldman S; Packer RJ; Willoughby M; Baker D; Garvin J; Strandjord S; Coccia P; Kaplan AM; Klemperer M; Finlay JL
    Bone Marrow Transplant; 2000 Jul; 26(2):153-60. PubMed ID: 10918425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.
    Peters WP; Eder JP; Henner WD; Schryber S; Wilmore D; Finberg R; Schoenfeld D; Bast R; Gargone B; Antman K
    J Clin Oncol; 1986 May; 4(5):646-54. PubMed ID: 3517240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
    Ager S; Mahendra P; Richards EM; Bass G; Baglin TP; Marcus RE
    Bone Marrow Transplant; 1996 Mar; 17(3):335-40. PubMed ID: 8704683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
    Antman K; Eder JP; Elias A; Shea T; Peters WP; Andersen J; Schryber S; Henner WD; Finberg R; Wilmore D
    Cancer Treat Rep; 1987 Feb; 71(2):119-25. PubMed ID: 3542208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.
    Colwill R; Crump M; Couture F; Danish R; Stewart AK; Sutton DM; Scott JG; Sutcliffe SB; Brandwein JM; Keating A
    J Clin Oncol; 1995 Feb; 13(2):396-402. PubMed ID: 7844600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
    Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
    J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.